Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapyTakuma Narita, Shinsuke Iida|Blood Cancer Journal|2015Cited by 49